Menu Menu


COVID-19 Research Pipeline


Registered/ Published






As at 1 April 2021
FILTERED BY > Remdesivir Clear filter

Taskforce recommendations for remdesivir unchanged following detailed analysis of disease severity subgroups

18 December, 2020
The Taskforce has completed a comprehensive review to assess the credibility of disease severity subgroups used in its recommendations on remdesivir. This was initiated following the World Health Organisation (WHO) decision to make a conditional recommendation against the use of remdesivir in all hospitalised patients, regardless of disease severity (20 November 2020). This differs from the Taskforce conditional recommendation supporting use in...

Weekly Communique # 36

17 December, 2020
Dear colleagues, It’s hard to fully comprehend a year like 2020. The pandemic has affected us all and no doubt its impact will continue and reverberate for some...

Weekly Communique # 31

12 November, 2020
WEEK IN REVIEW IPC Panel EOI for paediatric and clinical engineering expertise The Taskforce is calling for Expressions of Interest from suitably qualified individuals with paediatric or clinical...

Weekly Communique # 29

29 October, 2020
WEEK IN REVIEW Updates to the living guideline this week New recommendations Three new recommendations have been published covering: Triazavirin Other immunomodulatory agents (PIMS-TS) Aspirin and antithrombotic agents...

COVERAGE: A/Prof Julian Elliott on Trump treatment

7 October, 2020
Our Executive Director, A/Prof Julian Elliott spoke with Liam Mannix from The Age and Sydney Morning Herald about President Trump's treatment for COVID-19.      

Taskforce issues first recommendation for drug treatment for COVID-19

5 June, 2020
The National COVID-19 Clinical Evidence Taskforce today gave a conditional recommendation for use of remdesivir in treatment of people with COVID-19. The Taskforce is comprised of 28 peak health...
Media Release